Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis
Status:
Unknown status
Trial end date:
2020-03-15
Target enrollment:
Participant gender:
Summary
A randomised, double-blind, placebo-controlled, trial to evaluate the efficacy of brodalumab
monotherapy on vascular and systemic inflammation by 18F-FDG-PET/CT in subjects with
moderate-to-severe plaque-type psoriasis who are candidates for systemic therapy